RBC Capital Rates AbbVie (ABBV) Outperform, $280 Price Target

RBC Capital maintains its bullish stance on AbbVie with a price target of $280, a 1.93% downside from the current price.

By EarningsIQ Research Desk · Published Oct 16, 2026, 1:55 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

RBC Capital rated AbbVie Inc. ($ABBV) "Outperform" with a $280 price target on October 13, 2026.

Since the rating, $ABBV is up 4.7% to date (from the $272.69 close on Oct 13, 2026).

ABBV AbbVie Inc.

$285.42 +28.19% year to date

Daily close · Oct 16, 2026

Key Points

On October 13, 2026, RBC Capital reiterated its Outperform rating on AbbVie Inc. (NYSE: ABBV) with a price target of $280.
RBC Capital's $280 price target implies 1.93% downside from AbbVie Inc.'s ($ABBV) current $285.52 share price.
AbbVie shares recently traded around $285.52, which is about 2% above RBC's target.
The company's next earnings report is scheduled for October 29, 2026.

Get $ABBV trade alerts by text

We text you when insiders, Congress or big funds trade $ABBV. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated AbbVie Inc. alert may contain errors. Disclosures

RBC Capital reiterated its Outperform rating on AbbVie Inc. (NYSE: ABBV) on October 13, 2026, maintaining a price target of $280. This target is unchanged from its prior estimate and reflects RBC's continued positive outlook for the biopharmaceutical company.

AbbVie recently traded around $285.52, placing it about 2% above RBC's price target. This suggests that the stock is currently valued higher than what RBC expects in the near term. The company is known for its diverse portfolio of treatments, including options for autoimmune diseases and various cancers.

Other Institutional Activity in AbbVie

Several other institutional investors have also made adjustments to their positions in AbbVie. Blackrock Inc. reduced its holdings by 1,205,552 shares, leaving it with 149,488,412 shares worth approximately $42.67 billion. Meanwhile, Vanguard Capital Management LLC added 516,956 shares, increasing its total to 115,396,098 shares valued at about $32.94 billion. State Street Corporation grew its stake by 1,380,673 shares, ending with 82,596,748 shares worth roughly $23.58 billion. In contrast, Vanguard Portfolio Management LLC and JPMorgan Chase & Co. both trimmed their positions, with Vanguard reducing by 1,044,934 shares and JPMorgan cutting 8,880,294 shares.

AbbVie Inc. Stock Up 0.7%

AbbVie is currently trading above its target set by RBC Capital, highlighting a strong market position. The company's stock has shown resilience, trading well above its 52-week low. AbbVie has a solid growth outlook, with a revenue growth of 10.2% year-over-year, which is a positive sign for investors.

12-month forecast

$ABBV price target

AbbVie Inc. daily closes and this analyst's $280 target. Not advice.

Recent Earnings

For the trailing twelve months, AbbVie reported revenue of approximately $64.39 billion and earnings per share of $3.54. The company has a net margin of 9.8%, reflecting its efficiency in managing its operations. AbbVie is set to announce its next earnings report on October 29, 2026.

Earnings drift grade

Outlook vs expectations on the last report — not price action.

C+ 65/100

Reported Apr 29, 2026

Forward outlook
4 analysts raised price targets.
EPS & revenue
EPS met estimates. Revenue met estimates.
Profit surprise
EBITDA missed by 42 percent. Operating income missed by 72 percent.
Pre-earnings setup
Expectations were about average.
Analyst signal
4 target raises.
Earnings quality
Gross margin up 1.9 points. Operating margin up 3.6 points. Positive free cash flow.

Earnings Call Summary

AbbVie delivered strong first quarter results with $15 billion in sales and earnings per share of $2.65, beating expectations. Skyrizi sales hit $4.5 billion with 29 percent growth in psoriasis and inflammatory bowel disease markets. Rinvoq brought in $2.1 billion with 20 percent growth across rheumatology and gastroenterology, and the company is preparing to launch the drug in alopecia areata and vitiligo later this year.

Guidance The company raised full year earnings per share guidance to between $14.08 and $14.28, up $0.12. They now expect about $67.3 billion in total sales for the year. They also raised guidance for second quarter to about $16.7 billion in revenue and earnings per share between $3.74 and $3.78.

Fine but not compelling. Acceptable results that likely do not create a meaningful forward reset.

Dividend

AbbVie pays an annual dividend of $6.92 per share, yielding about 2.4%. The company has a high dividend payout ratio of 190.4%, indicating that it returns a significant portion of its earnings to shareholders.

Insider Buying and Selling at AbbVie Inc.

Insider transactions show some activity at AbbVie. Perry C. Siatis, General Counsel, sold 22,381 shares at an average price of $230.00 on February 25, 2026, totaling about $5.15 million. He also sold 18,668 shares on March 2, 2026, valued at approximately $4.38 million. Another officer, David Ryan Purdue, sold 5,230 shares at $233.56 on March 4, 2026, worth around $1.22 million. Nicholas Donoghoe, also an officer, sold 32,710 shares at $250.00 on August 14, 2026, totaling about $8.18 million.

Analysts Set New Price Targets

Earlier in October, several firms maintained their ratings on AbbVie. On October 8, JP Morgan kept its Overweight rating with a price target of $300.00, while Cantor Fitzgerald also maintained an Overweight rating with a target of $290.00. UBS held a Neutral rating with a target of $275.00. Guggenheim reiterated a Buy rating with a target of $288.00. The consensus among analysts remains positive, with a variety of price targets reflecting strong expectations for AbbVie’s performance.

About AbbVie

AbbVie Inc. is a biopharmaceutical company based in North Chicago, Illinois. It focuses on developing and selling a wide range of medicines and therapies, particularly in the fields of autoimmune diseases and cancer treatment. AbbVie is known for its innovative approaches in the healthcare sector, which is crucial as it navigates market dynamics and investor expectations.

Bottom Line

Investors should keep an eye on AbbVie as it approaches its next earnings date on October 29, 2026. With RBC Capital reaffirming its target, and various analysts maintaining positive ratings, there is a consistent belief in the company’s growth prospects.